Lipigon Pharmaceuticals OM:LPGO 주식 보고서 Lipigon Pharmaceuticals AB (publ)
OM:LPGO 주식 보고서
LPGO 주식 개요 리피곤 파마슈티컬스는 스웨덴에서 지질 관련 질환 치료제를 개발하는 회사입니다.
보상 위험 분석 + 1 더 많은 위험
모든 위험 점검 보기 Lipigon Pharmaceuticals AB (publ) 경쟁사 가격 내역 및 성능
다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Lipigon Pharmaceuticals 과거 주가 현재 주가 SEK 0.14 52주 최고치 SEK 0.60 52주 최저치 SEK 0.12 베타 0.58 11개월 변경 -44.44% 3개월 변경 사항 -58.76% 1년 변경 사항 -68.54% 33년 변화 -97.99% 5년 변화 n/a IPO 이후 변화 -98.61%
최근 뉴스 및 업데이트
Co-Founder & CEO recently bought kr75k worth of stock Sep 18
Co-Founder & CEO recently bought kr75k worth of stock Sep 15
Forecast to breakeven in 2026 Aug 30
New major risk - Financial position Aug 28
Co-Founder & CEO recently bought kr101k worth of stock Apr 24
The Swedish Medical Products Agency Approves Lipigon's Phase II Study with Lipisense Feb 08 더 많은 업데이트 보기
Co-Founder & CEO recently bought kr75k worth of stock Sep 18
Co-Founder & CEO recently bought kr75k worth of stock Sep 15
Forecast to breakeven in 2026 Aug 30
New major risk - Financial position Aug 28
Co-Founder & CEO recently bought kr101k worth of stock Apr 24
The Swedish Medical Products Agency Approves Lipigon's Phase II Study with Lipisense Feb 08
Co-Founder & CEO recently bought kr135k worth of stock Dec 22
Business Development Manager & Chairman exercised options to buy kr146k worth of stock. Dec 19
Lipigon Pharmaceuticals AB (Publ) Announces Lipisense Progressing to Phase II Trials Dec 13
Lipigon Pharmaceuticals AB (Publ) Reports A Statically Confirms reduction of target protein ANGPTL4 after repeate treatment with Lipisense ® Nov 24
Lipigon Applies for Clinical Trial Phase II for Lipisense Nov 15
New major risk - Revenue and earnings growth Aug 31
Co-Founder & CEO recently bought kr68k worth of stock Jul 24
Lipigon Pharmaceuticals AB (publ) Announces Positive Safety Results and Encouraging Target Engagement Data from the Phase I Lipisense Trial Jul 13
Lipigon Announces Further Positive Data from Phase I Trial of Lipisense Jan 20
Third quarter 2022 earnings released: kr0.36 loss per share (vs kr1.18 loss in 3Q 2021) Nov 26
Less than half of directors are independent Nov 16
Lipigon Pharmaceuticals AB (publ) Announces Positive Top-Line Data from Phase I Clinical Study of Lipisense Oct 06
Lipigon Pharmaceuticals AB (Publ) Announces Liver-Specific Treatment of Target Protein ANGPTL4 Is Effective and Safe Jun 10
Lipigon Pharmaceuticals AB Announces First-In-Human Phase I Trial with Lipigon's Lipid-Lowering Candidate Lipisense Jun 01
Lipigon Receives CTA Approval for Lipid-Lowering Candidate Lipisense Apr 28
No independent directors Apr 27
Lipigon Pharmaceuticals AB Confirms Patent Application for Drug Candidate Lipisense in US Mar 03
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Mar 01
Lipigon Pharmaceuticals AB (publ) Ready to Apply for Clinical Trials After Successful Completion of Preclinical Safety Studies Feb 03
Lipigon Pharmaceuticals AB (Publ) Completes Another Preclinical Study with Drug Candidate Lipisense Jan 16
Lipigon Announces Positive Results from Preclinical Study for Lipid-Lowering Drug Candidate Lipisense Dec 03
Third quarter 2021 earnings: Revenues in line with analyst expectations Nov 28
Lipigon Expands Collaboration with Hitgen by Selecting Second Target Mar 12 주주 수익률 LPGO SE Biotechs SE 마켓 7D -13.6% -0.3% 0.6% 1Y -68.5% 28.9% 22.5%
전체 주주 수익률 보기
수익률 대 산업: LPGO 지난 1년 동안 28.9 %를 반환한 Swedish Biotechs 업계보다 저조한 성과를 냈습니다.
수익률 대 시장: LPGO 지난 1년 동안 22.5 %를 반환한 Swedish 시장보다 저조한 성과를 냈습니다.
가격 변동성 Is LPGO's price volatile compared to industry and market? LPGO volatility LPGO Average Weekly Movement 12.3% Biotechs Industry Average Movement 9.0% Market Average Movement 5.5% 10% most volatile stocks in SE Market 11.0% 10% least volatile stocks in SE Market 3.2%
안정적인 주가: LPGO 의 주가는 지난 3개월 동안 변동성이 심했습니다.
시간에 따른 변동성: LPGO 의 주간 변동성 ( 12% )은 지난 1년 동안 안정적이었지만 여전히 Swedish 의 75%보다 높습니다. 주식.
회사 소개 리피곤 파마슈티컬스는 스웨덴에서 지질 관련 질환 치료제를 개발하는 회사입니다. 이 회사의 제품 파이프라인은 중증 고중성지방혈증 질환 치료를 위한 리피센스 프로젝트, 희귀 질환인 지방 이영양증 치료를 위한 유전자 치료 프로젝트, 급성 호흡곤란 증후군을 위한 RNA 신약 프로젝트로 구성되어 있습니다. 리피곤 파마슈티컬스는 이상지질혈증 치료를 위한 저분자 약물 개발을 위해 HitGen과 협력 계약을 체결했습니다.
자세히 보기 Lipigon Pharmaceuticals AB (publ) 기본 사항 요약 Lipigon Pharmaceuticals 의 수익과 매출은 시가총액과 어떻게 비교하나요? LPGO 기본 통계 시가총액 SEK 20.77m 수익(TTM ) -SEK 20.25m 수익(TTM ) SEK 9.33m
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) LPGO 손익 계산서(TTM ) 수익 SEK 9.33m 수익 비용 SEK 23.24m 총 이익 -SEK 13.91m 기타 비용 SEK 6.34m 수익 -SEK 20.25m
주당 순이익(EPS) -0.14 총 마진 -149.21% 순이익 마진 -217.19% 부채/자본 비율 0%
LPGO 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
